{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:47:26Z","timestamp":1794854846930,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000085","name":"Ontario HIV Treatment Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>New forms of HIV pre-exposure prophylaxis (PrEP) include long-acting injectables and topical microbicides, each with unique attributes that may appeal to distinct users. We used a discrete choice experiment to characterize preferences for new PrEP formulations among Toronto men who have sex with men. MSM undergoing anonymous HIV testing completed a discrete choice experiment with 12 choice sets by selecting their preferred option within each set. Each set included \u201cusual methods to prevent HIV\u201d (excluding PrEP) as one alternative and two hypothetical PrEP alternatives, which differed according formulation\/dosing, side effects (none\/mild), risk of drug resistance (none\/low\/moderate), and HIV prevention efficacy (50%, 65%, 80% or 99% risk reduction). We used mixed logistic regression to infer preferences for PrEP attributes and calculate the marginal rate of substitution between efficacy and other PrEP attributes. 306 men with median (interquartile range) age\u2009=\u200929 (25, 36) years participated, and reported 6 (3, 10) partners and 0 (0, 2) condomless receptive anal sex acts in the preceding six months. An on-demand pill was the most preferred formulation, followed by a monthly injection, daily pill, and on-demand rectal gel. Drug resistance was an important determinant of preferences if the risk was moderate, but not if it was low. The minimum efficacy required for an on-demand pill to be preferred over no PrEP was 32.6% (95%CI\u2009=\u200921.2\u201343.9%); for a daily pill, injections, and rectal gel, minimum efficacy was 57.9% (95%CI\u2009=\u200944.1\u201371.7%), 40.1% (27.0\u201353.2%), and 71.3% (60.5\u201382.1%), respectively. Attitudes towards PrEP formulations vary among men who have sex with men, with on-demand pills and monthly injections having the highest average preference scores. Understanding these preferences may help to predict uptake.<\/jats:p>","DOI":"10.1038\/s41598-021-01634-3","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T06:03:36Z","timestamp":1636956216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men: a discrete choice experiment"],"prefix":"10.1038","volume":"11","author":[{"given":"Darrell H. S.","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayoti","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zavare","family":"Tengra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor A.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Bayoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"issue":"27","key":"1634_CR1","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363(27), 2587\u20132599 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"1634_CR2","first-page":"00052","volume":"9","author":"S McCormack","year":"2015","unstructured":"McCormack, S. et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 9(15), 00052\u201300056 (2015).","journal-title":"Lancet"},{"issue":"23","key":"1634_CR3","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina, J. M. et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 373(23), 2237\u20132246 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1634_CR4","unstructured":"Molina, J. M. et al. On demand pre-exposure prophylaxis for HIV in men who have sex with men: An observational cohort study to assess efficacy, safety and impact on sexual behaviour. Lancet HIV 4(9), e402\u2013e410. (2017).Lancet HIV"},{"issue":"10246","key":"1634_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","volume":"396","author":"KH Mayer","year":"2020","unstructured":"Mayer, K. H. et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): Primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet 396(10246), 239\u2013254 (2020).","journal-title":"Lancet"},{"key":"1634_CR6","unstructured":"Landovitz, R. J., Donnell, D., Clement, M. E. et al. Pre-exposure prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men. In Abstract OAXLB01. AIDS 2020 (2020)."},{"issue":"5996","key":"1634_CR7","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.1193748","volume":"329","author":"Q Abdool Karim","year":"2010","unstructured":"Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996), 1168\u20131174 (2010).","journal-title":"Science"},{"issue":"5","key":"1634_CR8","first-page":"614","volume":"64","author":"RD Cranston","year":"2017","unstructured":"Cranston, R. D. et al. MTN-017: A rectal phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel. Clin. Infect. Dis. 64(5), 614\u2013620 (2017).","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"1634_CR9","doi-asserted-by":"publisher","first-page":"e0181607","DOI":"10.1371\/journal.pone.0181607","volume":"12","author":"A Carballo-Dieguez","year":"2017","unstructured":"Carballo-Dieguez, A. et al. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS ONE 12(7), e0181607. https:\/\/doi.org\/10.1371\/journal.pone.0181607 (2017).","journal-title":"PLoS ONE"},{"issue":"4","key":"1634_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1503\/cmaj.051625","volume":"175","author":"CE Hewitt","year":"2006","unstructured":"Hewitt, C. E., Torgerson, D. J. & Miles, J. N. V. Is there another way to take account of noncompliance in randomized controlled trials?. CMAJ 175(4), 347 (2006).","journal-title":"CMAJ"},{"issue":"7436","key":"1634_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/bmj.328.7436.360","volume":"328","author":"M Ryan","year":"2004","unstructured":"Ryan, M. Discrete choice experiments in health care. BMJ 328(7436), 360\u2013361 (2004).","journal-title":"BMJ"},{"issue":"3","key":"1634_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.17269\/s41997-018-0064-3","volume":"109","author":"J Rana","year":"2018","unstructured":"Rana, J. et al. Trends in the awareness, acceptability, and usage of HIV pre-exposure prophylaxis among at-risk men who have sex with men in Toronto. Can. J. Public Health 109(3), 342\u2013352 (2018).","journal-title":"Can. J. Public Health"},{"key":"1634_CR13","unstructured":"Ryan, M., Kolstad, J., Rockers, P. & Dolea, C. How to Conduct a Discrete Choice Experiment for Health Workforce Recruitment and Retention in Remote and Rural Areas: A User Guide with Case Studies.  Geneva, Switzerland: World Health Organization (2012)."},{"issue":"1","key":"1634_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson, F. et al. Constructing experimental designs for discrete-choice experiments: Report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health 16(1), 3\u201313 (2013).","journal-title":"Value Health"},{"issue":"1","key":"1634_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1477-7517-11-26","volume":"11","author":"L Lazarus","year":"2014","unstructured":"Lazarus, L. et al. Establishing a community-based participatory research partnership among people who use drugs in Ottawa: The PROUD cohort study. Harm. Reduct. J. 11(1), 26 (2014).","journal-title":"Harm. Reduct. J."},{"issue":"2","key":"1634_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hec.1697","volume":"21","author":"EW de Bekker-Grob","year":"2012","unstructured":"de Bekker-Grob, E. W., Ryan, M. & Gerard, K. Discrete choice experiments in health economics: A review of the literature. Health Econ. 21(2), 145\u2013172 (2012).","journal-title":"Health Econ."},{"issue":"4","key":"1634_CR17","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber, A. B. et al. Statistical methods for the analysis of discrete choice experiments: A report of the ISPOR conjoint analysis good research practices task force. Value Health 19(4), 300\u2013315 (2016).","journal-title":"Value Health"},{"issue":"7","key":"1634_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40273-017-0506-4","volume":"35","author":"E Lancsar","year":"2017","unstructured":"Lancsar, E., Fiebig, D. G. & Hole, A. R. Discrete choice experiments: A guide to model specification, estimation and software. Pharmacoeconomics 35(7), 697\u2013716 (2017).","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1634_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/QAI.0b013e318256b2f6","volume":"60","author":"DK Smith","year":"2012","unstructured":"Smith, D. K., Pals, S. L., Herbst, J. H., Shinde, S. & Carey, J. W. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J. Acquir. Immune Defic. Syndr. 60(4), 421\u2013427 (2012).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"6","key":"1634_CR20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/cid\/ciy321","volume":"67","author":"DJ Colby","year":"2018","unstructured":"Colby, D. J. et al. Acquisition of multidrug-resistant human immunodeficiency virus type 1 infection in a patient taking preexposure prophylaxis. Clin. Infect. Dis. 67(6), 962\u2013964 (2018).","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"1634_CR21","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1128\/AAC.45.10.2733-2739.2001","volume":"45","author":"P Barditch-Crovo","year":"2001","unstructured":"Barditch-Crovo, P. et al. Phase I\/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45(10), 2733\u20132739 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"1634_CR22","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1097\/00002030-200305230-00006","volume":"17","author":"M Louie","year":"2003","unstructured":"Louie, M. et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 17(8), 1151\u20131156 (2003).","journal-title":"AIDS"},{"issue":"6","key":"1634_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.7326\/M17-0520","volume":"167","author":"RM Gulick","year":"2017","unstructured":"Gulick, R. M. et al. Safety and tolerability of maraviroc-containing regimens to prevent HIV infection in women: A phase 2 randomized trial. Ann. Intern. Med. 167(6), 384\u2013393 (2017).","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"1634_CR24","first-page":"238","volume":"215","author":"RM Gulick","year":"2017","unstructured":"Gulick, R. M. et al. Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (HPTN 069\/ACTG A5305). J. Infect. Dis. 215(2), 238\u2013246 (2017).","journal-title":"J. Infect. Dis."},{"issue":"9987","key":"1634_CR25","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","volume":"385","author":"PE Sax","year":"2015","unstructured":"Sax, P. E. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials. Lancet 385(9987), 2606\u20132615 (2015).","journal-title":"Lancet"},{"key":"1634_CR26","unstructured":"Hare, C. B., Coll, J., Ruane, P., et al. The phase 3 DISCOVER study: Daily F\/TAF or F\/TDF for HIV preexposure prophylaxis. In Conference on Retroviruses and Opportunistic Infections (2019)."},{"issue":"5","key":"1634_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/09540121.2018.1557590","volume":"31","author":"A Dubov","year":"2019","unstructured":"Dubov, A., Ogunbajo, A., Altice, F. L. & Fraenkel, L. Optimizing access to PrEP based on MSM preferences: Results of a discrete choice experiment. AIDS Care 31(5), 545\u2013553 (2019).","journal-title":"AIDS Care"},{"issue":"6","key":"1634_CR28","doi-asserted-by":"publisher","first-page":"e25528","DOI":"10.1002\/jia2.25528","volume":"23","author":"AM Minnis","year":"2020","unstructured":"Minnis, A. M. et al. Preferences for long-acting Pre-Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: Results of a discrete choice experiment. J. Int. AIDS Soc. 23(6), e25528 (2020).","journal-title":"J. Int. AIDS Soc."},{"issue":"11","key":"1634_CR29","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1007\/s10461-015-1258-9","volume":"20","author":"PA Newman","year":"2016","unstructured":"Newman, P. A., Cameron, M. P., Roungprakhon, S., Tepjan, S. & Scarpa, R. Acceptability and preferences for hypothetical rectal microbicides among a community sample of young men who have sex with men and transgender women in Thailand: A discrete choice experiment. AIDS Behav. 20(11), 2588\u20132601 (2016).","journal-title":"AIDS Behav."},{"issue":"12","key":"1634_CR30","doi-asserted-by":"publisher","first-page":"e83193","DOI":"10.1371\/journal.pone.0083193","volume":"8","author":"F Terris-Prestholt","year":"2013","unstructured":"Terris-Prestholt, F. et al. How much demand for new HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. PLoS ONE 8(12), e83193 (2013).","journal-title":"PLoS ONE"},{"issue":"1","key":"1634_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/0272989X17729376","volume":"38","author":"M Quaife","year":"2018","unstructured":"Quaife, M. et al. Divergent preferences for HIV prevention: A discrete choice experiment for multipurpose HIV prevention products in South Africa. Med. Decis. Mak. 38(1), 120\u2013133 (2018).","journal-title":"Med. Decis. Mak."},{"issue":"10","key":"1634_CR32","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1007\/s10461-021-03253-5","volume":"25","author":"V Chakrapani","year":"2021","unstructured":"Chakrapani, V. et al. Willingness to use Pre-exposure Prophylaxis (PrEP) and preferences among men who have sex with men in Mumbai and Chennai, India: A discrete choice experiment. AIDS Behav. 25(10), 3074\u20133084 (2021).","journal-title":"AIDS Behav."},{"issue":"36","key":"1634_CR33","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1016\/j.vaccine.2013.05.089","volume":"31","author":"MP Cameron","year":"2013","unstructured":"Cameron, M. P., Newman, P. A., Roungprakhon, S. & Scarpa, R. The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine 31(36), 3712\u20133717 (2013).","journal-title":"Vaccine"},{"issue":"11","key":"1634_CR34","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/QAD.0b013e32833adbe8","volume":"24","author":"PA Newman","year":"2010","unstructured":"Newman, P. A. & Logie, C. HIV vaccine acceptability: A systematic review and meta-analysis. AIDS 24(11), 1749\u20131756 (2010).","journal-title":"AIDS"},{"issue":"10","key":"1634_CR35","first-page":"000000000000059","volume":"4","author":"T Palanee-Phillips","year":"2019","unstructured":"Palanee-Phillips, T. & Baeten, J. M. Topical delivery of long-acting antiretrovirals to prevent HIV acquisition. Curr. Opin. HIV AIDS. 4(10), 0000000000000598 (2019).","journal-title":"Curr. Opin. HIV AIDS."},{"key":"1634_CR36","doi-asserted-by":"publisher","first-page":"118574","DOI":"10.1016\/j.ijpharm.2019.118574","volume":"569","author":"YH Dallal Bashi","year":"2019","unstructured":"Dallal Bashi, Y. H. et al. Towards a dapivirine and levonorgestrel multipurpose vaginal ring: Investigations into the reaction between levonorgestrel and addition-cure silicone elastomers. Int. J. Pharm. 569, 118574. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118574 (2019).","journal-title":"Int. J. Pharm."},{"issue":"19","key":"1634_CR37","first-page":"30238","volume":"23","author":"LE Coelho","year":"2019","unstructured":"Coelho, L. E., Torres, T. S., Veloso, V. G., Landovitz, R. J. & Grinsztejn, B. Pre-exposure prophylaxis 2.0: New drugs and technologies in the pipeline. Lancet HIV 23(19), 30238\u201330233 (2019).","journal-title":"Lancet HIV"},{"issue":"22","key":"1634_CR38","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten, J. M. et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N. Engl. J. Med. 375(22), 2121\u20132132 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"1634_CR39","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel, A. et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N. Engl. J. Med. 375(22), 2133\u20132143 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"1634_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen, W. et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J. Acquir. Immune Defic. Syndr. 67(5), 481\u2013486 (2014).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"8","key":"1634_CR41","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","volume":"4","author":"M Markowitz","year":"2017","unstructured":"Markowitz, M. et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): A multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV 4(8), e331\u2013e340 (2017).","journal-title":"Lancet HIV"},{"key":"1634_CR42","unstructured":"City of Toronto 2016 Census Backgrounder Report: Housing, Immigration, Ethnicity & Aboriginal Peoples. Available at: https:\/\/www.toronto.ca\/city-government\/data-research-maps\/toronto-economy-labour-force-demographics\/. Accessed 10 September, 2021 (2016)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01634-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01634-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01634-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:32:19Z","timestamp":1670070739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01634-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-01634-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.32920\/25360306","asserted-by":"object"},{"id-type":"doi","id":"10.32920\/25360306.v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"assertion":[{"value":"1 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the past 3\u00a0years, DHST\u2019s institution has received research support for investigator-initiated research studies from Gilead and Abbvie, and DHST has been a Site Principal Investigator for clinical trials sponsored by Glaxo Smith Kline. Other authors have no financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22252"}}